20160621 CCMG-CSCC Symposium 3: CSCC

Maternal Serum Screening

Chair: Kareena Schnabl, University of Alberta Hospital

General Objectives: By the end of the symposium, participants will be able to:
1.   Evaluate the biochemical and molecular testing options available for prenatal screening of trisomies in Canada
2.   Describe and appreciate the technical aspects of cell free fetal DNA
3.   Outline the clinical impact of the inclusion of cell free fetal DNA testing to current testing guidelines and describe approaches taken in different Canadian provinces
4.   Appreciate the impact of the PEGASUS initiative on clinical practice

Question Title

* 1. Please asses the Sessions overrall

	Strongly Disagree	Disagree	Neutral	Agree	Strongly Agree
Sufficient time was allowed for audience participation/active learning	Sufficient time was allowed for audience participation/active learning Strongly Disagree	Sufficient time was allowed for audience participation/active learning Disagree	Sufficient time was allowed for audience participation/active learning Neutral	Sufficient time was allowed for audience participation/active learning Agree	Sufficient time was allowed for audience participation/active learning Strongly Agree
The facilities were satisfactory.	The facilities were satisfactory. Strongly Disagree	The facilities were satisfactory. Disagree	The facilities were satisfactory. Neutral	The facilities were satisfactory. Agree	The facilities were satisfactory. Strongly Agree
The session was free from commercial bias	The session was free from commercial bias Strongly Disagree	The session was free from commercial bias Disagree	The session was free from commercial bias Neutral	The session was free from commercial bias Agree	The session was free from commercial bias Strongly Agree
Overall, I would rate this Symposium as excellent	Overall, I would rate this Symposium as excellent Strongly Disagree	Overall, I would rate this Symposium as excellent Disagree	Overall, I would rate this Symposium as excellent Neutral	Overall, I would rate this Symposium as excellent Agree	Overall, I would rate this Symposium as excellent Strongly Agree

Please assess each Speaker by their Session:

Question Title

* 2. Prenatal screening for Down syndrome: The role of Biochemical markers

Speaker: Nathalie Lepage,
Head, Biochemical Genetics Laboratory, Children’s Hospital of Eastern Ontario

Objectives: At the end of this session, participants will be able to:
1. Describe the markers used for various protocols for Down syndrome screening.
2. Compare the screening performance of the various protocols.
3. Estimate the impact of patient characteristics on screening performance.

	Poor	Fair	Good	Very Good	Outstanding
Clarity of Voice	Clarity of Voice Poor	Clarity of Voice Fair	Clarity of Voice Good	Clarity of Voice Very Good	Clarity of Voice Outstanding
Met Stated Objectives	Met Stated Objectives Poor	Met Stated Objectives Fair	Met Stated Objectives Good	Met Stated Objectives Very Good	Met Stated Objectives Outstanding
Balanced & Unbiased	Balanced & Unbiased Poor	Balanced & Unbiased Fair	Balanced & Unbiased Good	Balanced & Unbiased Very Good	Balanced & Unbiased Outstanding
Relevant to Practice Overall	Relevant to Practice Overall Poor	Relevant to Practice Overall Fair	Relevant to Practice Overall Good	Relevant to Practice Overall Very Good	Relevant to Practice Overall Outstanding
Time for Active Learning	Time for Active Learning Poor	Time for Active Learning Fair	Time for Active Learning Good	Time for Active Learning Very Good	Time for Active Learning Outstanding

Comments

Question Title

* 3. Technical aspects and quality features of the NIPT noninvasive prenatal test

Speaker: Barry Hoffman,
Mount Sinai Hospital

Objectives: At the end of this session, participants will be able to:
1. Describe the common elements of the Noninvasive Prenatal Test [NIPT].
2. Compare the different NIPT assay designs available commercially to determine Trisomy 21.
3. Discuss analytical, physiological and clinical features that bear on the quality and rigour of NIPT.
4. Itemize strengths and limitations of NIPT.
5. Summarize briefly the clinical performance of NIPT.
6. Explain how fetal aneuploidy can be determined from cell free fetal DNA fragments circulating in the maternal blood.

	Poor	Fair	Good	Very Good	Outstanding
Clarity of Voice	Clarity of Voice Poor	Clarity of Voice Fair	Clarity of Voice Good	Clarity of Voice Very Good	Clarity of Voice Outstanding
Met Stated Objectives	Met Stated Objectives Poor	Met Stated Objectives Fair	Met Stated Objectives Good	Met Stated Objectives Very Good	Met Stated Objectives Outstanding
Balanced & Unbiased	Balanced & Unbiased Poor	Balanced & Unbiased Fair	Balanced & Unbiased Good	Balanced & Unbiased Very Good	Balanced & Unbiased Outstanding
Relevant to Practice Overall	Relevant to Practice Overall Poor	Relevant to Practice Overall Fair	Relevant to Practice Overall Good	Relevant to Practice Overall Very Good	Relevant to Practice Overall Outstanding
Time for Active Learning	Time for Active Learning Poor	Time for Active Learning Fair	Time for Active Learning Good	Time for Active Learning Very Good	Time for Active Learning Outstanding

Comments

Question Title

* 4. Options for prenatal screening for trisomies in Canada

Speaker: Radha Chari,
Chair Department Ob-Gyn, Zone Department Head, University of Alberta, Alberta Health Services

Objectives: At the end of this session, participants will be able to:
1. Compare the different options for screening.
2. Explain NIPT.
3. Compare NIPT to other biochemical screening options.
4. Summarize different approaches available in Canada.

	Poor	Fair	Good	Very Good	Outstanding
Clarity of Voice	Clarity of Voice Poor	Clarity of Voice Fair	Clarity of Voice Good	Clarity of Voice Very Good	Clarity of Voice Outstanding
Met Stated Objectives	Met Stated Objectives Poor	Met Stated Objectives Fair	Met Stated Objectives Good	Met Stated Objectives Very Good	Met Stated Objectives Outstanding
Balanced & Unbiased	Balanced & Unbiased Poor	Balanced & Unbiased Fair	Balanced & Unbiased Good	Balanced & Unbiased Very Good	Balanced & Unbiased Outstanding
Relevant to Practice Overall	Relevant to Practice Overall Poor	Relevant to Practice Overall Fair	Relevant to Practice Overall Good	Relevant to Practice Overall Very Good	Relevant to Practice Overall Outstanding
Time for Active Learning	Time for Active Learning Poor	Time for Active Learning Fair	Time for Active Learning Good	Time for Active Learning Very Good	Time for Active Learning Outstanding

Comments

Question Title

* 5. As a result of attending this session, I am planning to:

a) Discuss the session with my colleagues

b) Pursue additional learning activities.

c) Complete a Personal Learning Project.

d) Not change my practice.

e) Change my practice.

Question Title

* 6. Please explain any changes you plan to make or personal learning projects you will pursue as a result of this session:

Question Title

* 7. Please indicate which CanMEDS roles you felt were addressed during this educational activity. (Select all that apply)

Medical Expert

Communicator

Collaborator

Manager

Health Advocate

Scholar

Professional

20160621 CCMG-CSCC Symposium 3: CSCC

Maternal Serum Screening

Question Title

* 1. Please asses the Sessions overrall

Question Title

Question Title

Question Title

Question Title

* 5. As a result of attending this session, I am planning to:

Question Title

* 6. Please explain any changes you plan to make or personal learning projects you will pursue as a result of this session:

Question Title

* 7. Please indicate which CanMEDS roles you felt were addressed during this educational activity. (Select all that apply)

Question Title

* 8. General comments about individual speaker:

Question Title

* 9. What topics would you like to be addressed at future conferences to keep you up to date in your profession?